JP5252459B2 - リボフラノシルピリミジンヌクレオシドの調製 - Google Patents

リボフラノシルピリミジンヌクレオシドの調製 Download PDF

Info

Publication number
JP5252459B2
JP5252459B2 JP2009532372A JP2009532372A JP5252459B2 JP 5252459 B2 JP5252459 B2 JP 5252459B2 JP 2009532372 A JP2009532372 A JP 2009532372A JP 2009532372 A JP2009532372 A JP 2009532372A JP 5252459 B2 JP5252459 B2 JP 5252459B2
Authority
JP
Japan
Prior art keywords
aryl
formula
methyl
fluoro
tetrahydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009532372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505954A5 (https=
JP2010505954A (ja
Inventor
スティーブン， ディー． アクスト，
ケシャブ サルマ，
ジャスティン ヴィターレ，
ジャン ジュ，
ブルース ロス，
スグナ ラチャコンダ，
キンウー ジン，
ビョン−クォン チュン，
Original Assignee
ギリアド ファーマセット エルエルシー
エフ． ホフマン ラ−ロシュ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアド ファーマセット エルエルシー, エフ． ホフマン ラ−ロシュ アーゲー filed Critical ギリアド ファーマセット エルエルシー
Publication of JP2010505954A publication Critical patent/JP2010505954A/ja
Publication of JP2010505954A5 publication Critical patent/JP2010505954A5/ja
Application granted granted Critical
Publication of JP5252459B2 publication Critical patent/JP5252459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009532372A 2006-10-10 2007-10-05 リボフラノシルピリミジンヌクレオシドの調製 Active JP5252459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85096206P 2006-10-10 2006-10-10
US60/850,962 2006-10-10
PCT/US2007/021548 WO2008045419A1 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines

Publications (3)

Publication Number Publication Date
JP2010505954A JP2010505954A (ja) 2010-02-25
JP2010505954A5 JP2010505954A5 (https=) 2013-04-04
JP5252459B2 true JP5252459B2 (ja) 2013-07-31

Family

ID=39111500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009532372A Active JP5252459B2 (ja) 2006-10-10 2007-10-05 リボフラノシルピリミジンヌクレオシドの調製

Country Status (18)

Country Link
US (2) US8912321B2 (https=)
EP (1) EP2084174B1 (https=)
JP (1) JP5252459B2 (https=)
KR (1) KR101057239B1 (https=)
CN (1) CN101600725B (https=)
AU (1) AU2007307057B2 (https=)
BR (1) BRPI0719174A2 (https=)
CA (1) CA2666098C (https=)
DK (1) DK2084174T3 (https=)
ES (1) ES2429290T3 (https=)
GT (1) GT200900080A (https=)
IL (1) IL198086A (https=)
MX (1) MX2009003795A (https=)
PL (1) PL2084174T3 (https=)
PT (1) PT2084174E (https=)
RU (1) RU2421461C2 (https=)
SI (1) SI2084174T1 (https=)
WO (1) WO2008045419A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9098916B2 (en) 2004-11-17 2015-08-04 Thomson Licensing Bit-accurate film grain simulation method based on pre-computed transformed coefficients
US9117261B2 (en) 2004-11-16 2015-08-25 Thomson Licensing Film grain SEI message insertion for bit-accurate simulation in a video system
US9177364B2 (en) 2004-11-16 2015-11-03 Thomson Licensing Film grain simulation method based on pre-computed transform coefficients
US10715834B2 (en) 2007-05-10 2020-07-14 Interdigital Vc Holdings, Inc. Film grain simulation based on pre-computed transform coefficients

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
AU2005285045B2 (en) * 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
SG194404A1 (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
JP5716500B2 (ja) 2010-06-03 2015-05-13 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類前駆体の製造方法
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
CN104379591A (zh) 2012-05-29 2015-02-25 弗·哈夫曼-拉罗切有限公司 用于制备2-脱氧-2-氟-2-甲基-d-呋喃核糖基核苷化合物的方法
CN103450148B (zh) * 2012-06-04 2018-06-12 浙江九洲药业股份有限公司 一种五元环硫酸酯化合物的合成方法
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CN103012386B (zh) * 2012-12-26 2015-04-01 浙江普洛得邦制药有限公司 一种五元环状硫酸酯的制备方法
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
CN104744539A (zh) * 2014-09-19 2015-07-01 上海皓元生物医药科技有限公司 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的合成方法
CN104327138B (zh) * 2014-10-21 2017-05-10 齐鲁制药有限公司 Psi‑7977中间体化合物的制备方法
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104610404B (zh) * 2015-01-16 2016-04-06 南通常佑药业科技有限公司 一种呋喃核糖磷酸酯衍生物的制备方法
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN104829672B (zh) * 2015-05-19 2018-03-13 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN105061535A (zh) * 2015-09-02 2015-11-18 江苏科本医药化学有限公司 一种索非布韦中间体的合成方法
CN106554333B (zh) * 2015-09-29 2018-11-30 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN106608896B (zh) * 2015-10-26 2019-08-27 江苏福瑞康泰药业有限公司 一种药物中间体的合成方法
CN105418547A (zh) * 2015-11-17 2016-03-23 海门慧聚药业有限公司 索非布韦关键中间体的制备
CN105503983B (zh) * 2015-12-17 2019-06-28 江苏阿尔法药业有限公司 索菲布韦中间体及其衍生物的制备方法
CN105566422B (zh) * 2015-12-29 2019-06-25 江苏阿尔法药业有限公司 索菲布韦中间体或其衍生物的制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
CN106810515A (zh) * 2017-02-06 2017-06-09 抚州市星辰药业有限公司 一种合成索非布韦的中间体化合物及其合成方法
CN109422789A (zh) * 2017-08-28 2019-03-05 常州制药厂有限公司 一种索非布韦的制备工艺改进方法
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN108675984A (zh) * 2018-06-22 2018-10-19 江苏阿尔法药业有限公司 索非布韦中间体的制备方法
CN111606961A (zh) * 2019-02-26 2020-09-01 顾世海 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的工艺生产方法
CN111040010A (zh) * 2019-12-23 2020-04-21 上海红蓝医药科技有限公司 一种索非布韦中间体的合成方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850002973A (ko) * 1983-10-03 1985-05-28 구라바야시 이꾸시로 시티딘 유도체의 제조방법
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
KR100719606B1 (ko) * 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
SK1512002A3 (en) 1999-07-30 2002-11-06 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
BR0312271A (pt) 2002-06-28 2007-11-06 Idenix Cayman Ltd compostos, composições e seus usos para o tratamento de infecções por flaviviridae
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
CN1863813B (zh) * 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
EP1741716B8 (en) * 2004-04-30 2012-02-22 Daiichi Sankyo Company, Limited Process for producing pentacyclic taxane
AU2005267051B2 (en) 2004-07-21 2011-07-14 Gilead Sciences, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
AU2005285045B2 (en) * 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9117261B2 (en) 2004-11-16 2015-08-25 Thomson Licensing Film grain SEI message insertion for bit-accurate simulation in a video system
US9177364B2 (en) 2004-11-16 2015-11-03 Thomson Licensing Film grain simulation method based on pre-computed transform coefficients
US9098916B2 (en) 2004-11-17 2015-08-04 Thomson Licensing Bit-accurate film grain simulation method based on pre-computed transformed coefficients
US10715834B2 (en) 2007-05-10 2020-07-14 Interdigital Vc Holdings, Inc. Film grain simulation based on pre-computed transform coefficients

Also Published As

Publication number Publication date
IL198086A (en) 2012-03-29
WO2008045419A1 (en) 2008-04-17
PL2084174T3 (pl) 2013-12-31
CN101600725A (zh) 2009-12-09
EP2084174B1 (en) 2013-07-31
CA2666098C (en) 2012-09-25
RU2421461C2 (ru) 2011-06-20
AU2007307057A1 (en) 2008-04-17
AU2007307057B2 (en) 2011-09-15
US20080139802A1 (en) 2008-06-12
JP2010505954A (ja) 2010-02-25
KR101057239B1 (ko) 2011-08-16
SI2084174T1 (sl) 2013-10-30
HK1133889A1 (en) 2010-04-09
BRPI0719174A2 (pt) 2017-06-13
RU2009117396A (ru) 2010-11-20
DK2084174T3 (da) 2013-11-04
US8912321B2 (en) 2014-12-16
CN101600725B (zh) 2014-11-26
GT200900080A (es) 2012-04-10
ES2429290T3 (es) 2013-11-14
IL198086A0 (en) 2009-12-24
MX2009003795A (es) 2009-06-18
EP2084174A1 (en) 2009-08-05
KR20090060460A (ko) 2009-06-12
US20100056770A1 (en) 2010-03-04
PT2084174E (pt) 2013-10-08
CA2666098A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
JP5252459B2 (ja) リボフラノシルピリミジンヌクレオシドの調製
JP2010505954A5 (https=)
EP0342203B1 (en) 2',3' dideoxyribofuranoxide derivatives
EP0717748B1 (fr) Composes 2' ou 3'-deoxy- et 2', 3'-dideoxy-beta-l-pentofuranonucleosides, procede de preparation et application therapeutique, notamment anti-virale
EP2855497B1 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
JP6270742B2 (ja) 架橋型核酸誘導体の製造方法
JP2010512365A (ja) ４’−アジドシチジン誘導体の製造方法
JP2004538318A (ja) リバビリンの調製法
CN102171195B (zh) 合成地西他滨
CA2442979C (en) Process for the preparation of 2'-halo-.beta.-l-arabinofuranosyl nucleosides
US20160115191A1 (en) Novel Polymorph of Regadenoson
JP2010521452A (ja) Ｉｂ‐ｍｅｃａの合成方法
HK1133889B (en) Preparation of nucleosides ribofuranosyl pyrimidines
CN114456169A (zh) 3′-脱氧-3′,4′-二脱氢核糖核苷类似物及其制备方法
JP2006516249A (ja) ２−デオキシ−ｄ−グルコースの合成方法
Huang et al. Synthesis of (±)-cis-1-[2-(Hydroxymethyl)-1, 3-Oxathiolan-5-yl] cytosine and Its (±)-trans Isomer
TW202521548A (zh) 用於製備３－經取代５－胺基－６Ｈ－噻唑并［４，５－ｄ］嘧啶－２，７－二酮化合物之方法
HK1148738A (en) Process for production of ethynylthymidine compound using 5-methyluridine as starting raw material
JPH08134065A (ja) ３’−アミノ−３’−デオキシヌクレオシドの製造方法及びその合成中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120928

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130409

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5252459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160426

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250